

ABSTRACT

Neurooncol Pract. 2022 Sep 10;9(6):552-558. doi: 10.1093/nop/npac071.
eCollection 2022 Dec.

Neuro-oncology at the American Society for Clinical Oncology 2022 Annual Meeting.

Lukas RV(1)(2), Chmura SJ(3), Parney IF(4), Mammoser A(5), Smith SM(6), Li J(7).

Author information:

(1)Department of Neurology, Northwestern University, Chicago, Illinois, USA.

(2)Lou and Jean Malnati Brain Tumor Institute, Northwestern University, Chicago, Illinois, USA.

(3)Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois, USA.

(4)Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA.

(5)Department of Neurosurgery, Louisiana State University, New Orleans, Louisiana, USA.

(6)Department of Medicine, Section of Hematology and Oncology, University of Chicago, Chicago, Illinois, USA.

(7)Department of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, USA.

In the following brief report, we highlight the advances in the neuro-oncology space from the ASCO 2022 Annual Meeting. We put into context the phase 2 and 3 trials and how these may alter the standard of care going forward. In addition, we highlight some other earlier work that will lead to future and potentially practice-changing trials.

© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

DOI: 10.1093/nop/npac071

PMCID: PMC9665054

PMID: 36388417